東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Effects of EGCG and DAC Combinationa...

Wang, Zixu.

Linked to FindBook

Google Book

Amazon

博客來

Effects of EGCG and DAC Combinational Treatment on Treating Triple Negative Breast Cancer and Aiding Immune Checkpoint Blockage Therapies.

Record Type:	Electronic resources : Monograph/item
Title/Author:	Effects of EGCG and DAC Combinational Treatment on Treating Triple Negative Breast Cancer and Aiding Immune Checkpoint Blockage Therapies./
Author:	Wang, Zixu.
Published:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
Description:	34 p.
Notes:	Source: Masters Abstracts International, Volume: 80-12.
Contained By:	Masters Abstracts International80-12.
Subject:	Pharmacology. -
Online resource:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13813333
ISBN:	9781392197578

Effects of EGCG and DAC Combinational Treatment on Treating Triple Negative Breast Cancer and Aiding Immune Checkpoint Blockage Therapies.
Wang, Zixu.

Effects of EGCG and DAC Combinational Treatment on Treating Triple Negative Breast Cancer and Aiding Immune Checkpoint Blockage Therapies. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 34 p.

Source: Masters Abstracts International, Volume: 80-12.

Thesis (M.S.)--Sackler School of Graduate Biomedical Sciences (Tufts University), 2019.

This item must not be sold to any third party vendors.

Triple-negative breast cancer (TNBC) is a type of breast cancer that has decreased expression of progesterone receptor (PR) and estrogen receptor (ER), with no overexpression level of human epidermal growth factor receptor 2 (Her2). TNBC is most difficult to treat due to lack of druggable targets, high rates of recurrence and metastasis and resistance to immunotherapy. One of the common changes observed in TNBC is activation of Wnt signaling. Based on prior work, the Yee lab designed a combinational therapy that was likely to activate inhibitors of Wnt signaling and potentially alter TNBC. Epigallocatechin-3-gallate (EGCG) and decitabine (DAC), prior studies using this combination showed reduce Wnt signaling, inhibition of TNBC tumor growth and reduced distal metastasis. In this study, we show EGCG/DAC treatment of mouse models of TNBC increases immunogenicity, including 1) immune cell infiltration into the tumor microenvironment, 2) up-regulation of IFN signaling, 3) increased expression of viral mimicry genes. Furthermore, EGCG/DAC increases E-cadherin expression, suggesting a mechanism of the reduction in metastasis. In conclusion, EGCG/DAC treatment inhibits TNBC tumor growth, inhibits Wnt signaling, and regulates expression of immune checkpoints on both T cells and tumor cells, making EGCG/DAC a possible adjuvant for immune checkpoint therapy.

ISBN: 9781392197578Subjects--Topical Terms:

634543
Pharmacology.

Effects of EGCG and DAC Combinational Treatment on Treating Triple Negative Breast Cancer and Aiding Immune Checkpoint Blockage Therapies.
LDR:02558nmm a2200349 4500 001 2207277
005 20190916101813.5
008 201008s2019 ||||||||||||||||| ||eng d
020 $a 9781392197578
035 $a (MiAaPQ)AAI13813333
035 $a (MiAaPQ)tuftssackler:10570
035 $a AAI13813333
040 $a MiAaPQ $c MiAaPQ
100 1 $a Wang, Zixu. $3 3434245
245 1 0 $a Effects of EGCG and DAC Combinational Treatment on Treating Triple Negative Breast Cancer and Aiding Immune Checkpoint Blockage Therapies.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 34 p.
500 $a Source: Masters Abstracts International, Volume: 80-12.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Yee, Amy S.
502 $a Thesis (M.S.)--Sackler School of Graduate Biomedical Sciences (Tufts University), 2019.
506 $a This item must not be sold to any third party vendors.
520 $a Triple-negative breast cancer (TNBC) is a type of breast cancer that has decreased expression of progesterone receptor (PR) and estrogen receptor (ER), with no overexpression level of human epidermal growth factor receptor 2 (Her2). TNBC is most difficult to treat due to lack of druggable targets, high rates of recurrence and metastasis and resistance to immunotherapy. One of the common changes observed in TNBC is activation of Wnt signaling. Based on prior work, the Yee lab designed a combinational therapy that was likely to activate inhibitors of Wnt signaling and potentially alter TNBC. Epigallocatechin-3-gallate (EGCG) and decitabine (DAC), prior studies using this combination showed reduce Wnt signaling, inhibition of TNBC tumor growth and reduced distal metastasis. In this study, we show EGCG/DAC treatment of mouse models of TNBC increases immunogenicity, including 1) immune cell infiltration into the tumor microenvironment, 2) up-regulation of IFN signaling, 3) increased expression of viral mimicry genes. Furthermore, EGCG/DAC increases E-cadherin expression, suggesting a mechanism of the reduction in metastasis. In conclusion, EGCG/DAC treatment inhibits TNBC tumor growth, inhibits Wnt signaling, and regulates expression of immune checkpoints on both T cells and tumor cells, making EGCG/DAC a possible adjuvant for immune checkpoint therapy.
590 $a School code: 0845.
650 4 $a Pharmacology. $3 634543
650 4 $a Public health. $3 534748
650 4 $a Physiology. $3 518431
650 4 $a Oncology. $3 751006
690 $a 0419
690 $a 0573
690 $a 0719
690 $a 0992
710 2 $a Sackler School of Graduate Biomedical Sciences (Tufts University). $b Pharmacology and Drug Development. $3 3434240
773 0 $t Masters Abstracts International $g 80-12.
790 $a 0845
791 $a M.S.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13813333